Hemostatic markers of endothelial injury in ischaemic stroke caused by large or small vessel disease;Hemostatyczne wskaźniki uszkodzenia śródbłonka w udarze niedokrwiennym spowodowanym choroba̧ dużych lub małych naczyń

Polski Merkuriusz Lekarski

Volumn 21, Issue 125, 2006, Pages 429-433

  Iskra, Tomasz ^a   Turaj, Wojciech ^a   Słowik, Agnieszka ^a   Zwolińska, Grazyna ^a   Strojny, Jacek ^b   Szczudlik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF AGRICULTURE IN KRAKOW   (Poland)

Author keywords

Etiology; Haemostatic risk factors; Ischaemic stroke; Large vessel disease; Small vessel disease

Indexed keywords

BETA THROMBOGLOBULIN; FIBRINOGEN; HEMOSTATIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR; VON WILLEBRAND FACTOR;

ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DEMOGRAPHY; ECHOCARDIOGRAPHY; ENDOTHELIUM INJURY; FIBRINOGEN BLOOD LEVEL; HUMAN; INFANT; RISK FACTOR; VASCULAR DISEASE;

BETA-THROMBOGLOBULIN; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BRAIN ISCHEMIA; CEREBRAL ARTERIES; CEREBRAL VEINS; CEREBROVASCULAR ACCIDENT; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 33845334854     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Adams H.P. Jr, Bendixen B.H., Kappelle L.J. i wsp.: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org. 10172 in Acute Stroke Treatment. Stroke, 1993, 24, 35-41.
2. Badimon L., Badimon J.J., Chesebro J.H. i wsp.: Von Willebrand Factor and cardiovascular disease. Thromb. Haemost., 1993, 70, 111-118.
3. Blann A., Kumar P., Krupiński J., i wsp.: Soluble intercelluar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke. Blood Coagul. Fibrinolysis, 1999, 10, 277-284.
4. Bots M.L., Elwood P.C., Salonen J.T. i wsp.: Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J. Epidemiol. Community Health, 2002, 56, supl. 1, 114-118.
5. Catto A.J., Carter A.M., Barrett J.H., i wsp.: Von Willebrand factor and factor VIIIc in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb. Haemost., 1997, 77, 1104-1108.
6. Dembińska-Kieć A., Naskalski J.: Diagnostyka laboratoryjna z elementami biochemii klinicznej. Volumed, Urban & Partner, Wrocław 2002.
7. Ernst E.: The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis, 1993, 100, 1-12.
8. Folsom A.R., Rosamond W.D., Shahar E. i wsp.: Prospective study of markers of hemostatic function with risk of ischaemic stroke. Circulation, 1999, 100, 736-742.
9. Giroud M., Dutriltaux F., Lemesle M. i wsp.: Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different. Neurol. Res., 1998, 20, 15-18.
10. Hamsten A., Iselius L., de Faire U. i wsp.: Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet, 1987, 2, 988-991.
11. Hoekstra T., Geleijnse J.M., Kluft C. i wsp.: 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke, 2003, 34, 2822-2829.
12. Ip J.H., Fuster V., Badimion L. i wsp.: Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J. Am. Coll. Cardiol., 1990, 15, 1667-1687.
13. Iskra T., Turaj W., Słowik A. i wsp.: Fenotyp LDL u chorych z udarem niedokrwiennym mózgu. Przegl. Lek., 2002, 59, 7-10.
14. Islim I., Bareford D., Ebanks M. i wsp.: The role of platelets in essential hypertension. Blood Press., 1995, 4, 199-214.
15. Iwamoto T., Kubo H., Takasaki M. i wsp.: Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease. Stroke, 1995, 26, 52-56.
16. Johansson L., Jansson J., Boman K. i wsp.: Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/ plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke, 2000, 31, 26-32.
17. Kannel W.B., Wolf P.A., Castelli W.P. i wsp.: Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA, 1987, 258, 1183-1186.
18. Kario K., Matsuo T., Kobayashi H. i wsp.: "Silent" cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Ip(a) levels in elderly Japanese. Arterioscler. Thromb. Vasc. Biol., 1996, 16, 734-741.
19. Kohler H.P., Grant P.J.: Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med., 2000, 342, 1792-1801.
20. Kristensen B., Malm J., Nilsson T.K. i wsp.: Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke. Stroke, 1998, 29, 2261-2267.
21. Landolfi R., Scabbia E., Accorra F. i wsp.: Beta-thromboglobulin in patients with acute and chronic coronary artery disease. Acta Cardiol., 1982, 37, 325-332.
22. Lindgren A., Lindoff C., Norrving B. i wsp.: Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke, 1996, 27, 1066-1071.
23. Luttun A., Lupu F., Storkebaum E.: Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 499-505.
24. Mettinger K.L.: A study of hemostasis in ischemic cerebrovascular disease. I. Abnormalities in factor VIII and antithrombin. Thromb. Res., 1982, 26, 183-192.
25. Report of the WHO task force on stroke and other cerebrovascular diseases: Stroke - 1989. Recommendations on stroke prevention, diagnosis and therapy. Stroke, 1989, 20, 1407-1431.
26. Robertson R.M., Robertson D., Friesinger G.C. i wsp.: Platelet aggregates in peripheral and coronary-sinus blood in patients with spontaneous coronary-artery spasm. Lancet, 1980, 2, 829-831.
27. Shah A.B., Beamer N., Coull B.M.: Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke, 1985, 16, 643-647.
28. Słowik A., Iskra T., Turaj W. i wsp.: LDL phenotypes and other lipid abnormalities in large and small vessel disease. J. Neurol. Sci., 2003, 214, 11-16.
29. Smith E., Keeng G., Grant A. i wsp.: Fate of fibrinogen in human arterial intima. Arteriosclerosis, 1990, 10, 263-275.
30. Thompson S.G., Kienast J., Pyke S.D. i wsp.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med., 1995, 332, 635-641.
31. Tohgi H., Takahashi H., Chiba K. i wsp.: Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke, 1993, 24, 801-804.
32. Woo E., Huang C.Y., Chan V. i wsp.: Beta-thromboglobulin in cerebral infarction. J. Neurol. Neurosurg. Psychiatry, 1988, 51, 557-562.
33. Zahavi J., Price A.J., Westwick J. i wsp.: Enhanced in-vivo platelet release reaction, increased thromboxane synthesis, and decreased prostacyclin release after tourniquet ischaemia. Lancet, 1980, 2, 663-667.